EJNMMI physics · 2025
Establishment of a practical methodology for evaluating equieffective dose of individual patients based on RT-PHITS.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sato Tatsuhiko, Furuta Takuya, Sasaki Hidetaka, Watabe Tadashi
Аннотация
BACKGROUND: The RadioTherapy package based on PHITS (RT-PHITS) is an individual dosimetry system applicable to both targeted radionuclide therapy (TRT) and external radiotherapy. This study aims to establish a practical methodology for evaluating both absorbed doses and equieffective doses (EQDX) by improving RT-PHITS.
METHODS: We developed an Excel-based program, ExPORT-PHITS, which simplifies the conversion of the dose rates of specific organs and tumors calculated by RT-PHITS into corresponding absorbed doses and EQDX. ExPORT-PHITS offers two options for evaluating EQDX, each adopting a different type of microdosimetric kinetic model, to assess its dependence. The performance of the improved RT-PHITS, including ExPORT-PHITS, was evaluated using SPECT/CT images of two castration-resistant prostate cancer patients with bone metastases after the injection of 223RaCl2 and 99mTc-MDP.
RESULTS: Reasonable agreement was observed between absorbed doses calculated by RT-PHITS, IDAC Dose 2.1, and MIRDcalc, although absorbed doses in normal organs following the injection of 223RaCl2 were comparatively higher than those reported in other studies. Results for 223RaCl2 also showed that EQD2 tended to exceed the corresponding absorbed doses and RBE-weighted doses, while the relation was reversed for the injection of 99mTc-MDP.
CONCLUSIONS: These findings underscore RT-PHITS as a valuable tool for accurately modeling and optimizing individual TRT, especially for treatments involving α-ray emitters.
METHODS: We developed an Excel-based program, ExPORT-PHITS, which simplifies the conversion of the dose rates of specific organs and tumors calculated by RT-PHITS into corresponding absorbed doses and EQDX. ExPORT-PHITS offers two options for evaluating EQDX, each adopting a different type of microdosimetric kinetic model, to assess its dependence. The performance of the improved RT-PHITS, including ExPORT-PHITS, was evaluated using SPECT/CT images of two castration-resistant prostate cancer patients with bone metastases after the injection of 223RaCl2 and 99mTc-MDP.
RESULTS: Reasonable agreement was observed between absorbed doses calculated by RT-PHITS, IDAC Dose 2.1, and MIRDcalc, although absorbed doses in normal organs following the injection of 223RaCl2 were comparatively higher than those reported in other studies. Results for 223RaCl2 also showed that EQD2 tended to exceed the corresponding absorbed doses and RBE-weighted doses, while the relation was reversed for the injection of 99mTc-MDP.
CONCLUSIONS: These findings underscore RT-PHITS as a valuable tool for accurately modeling and optimizing individual TRT, especially for treatments involving α-ray emitters.